The University of Denver is responsible for ensuring that activities involving recombinant DNA or select agents and other biological hazards at the University of Denver are in compliance with established National Institutes of Health (NIH) Guidelines for research involving recombinant DNA molecules or select agents and other biological hazards. This authority is placed with the Institutional Biosafety Committee (Committee/IBC).
Research Involving Recombinant DNA
The IBC reviews and approves all proposals that anticipate use of DNA material. Please submit your IBC application via eprotocol. If you have any questions regarding research involving recombinant DNA, contact email@example.com.
The University of Denver requires that all use of recombinant DNA be registered with the Institutional Biosafety Committee. Many common uses of recombinant DNA, however, qualify for exemption under Section III-F of the NIH Guidelines. If your use of recombinant DNA qualifies for an exemption under these criteria, please fill out the IBC application via eprotocol. After review, the IBC will provide an exemption decision. If any changes are made to protocols for a study that has received an exemption from the IBC, an amendment must be submitted to the IBC.
If your use of recombinant DNA does not meet any of the exemption criteria above you must submit an application and undergo a full review by the IBC.
The NIH Guidelines states that "...any significant problems, violations of the NIH Guidelines, or any significant research-related accidents and illnesses" must be reported to NIH OBA within 30 days. Certain types of accidents must be reported on a more expedited basis. Spills or accidents in BL2, BL3 and BL4 must be immediately reported to NIH OBA. Please contact Research Compliance at firstname.lastname@example.org.
If you would like copies of the IBC minutes, please contact email@example.com or call 303-871-4050.